

Recurrent stroke in childhood cancer survivors

Heather J. Fullerton, MD, MAS
Kayla Stratton, MS
Sabine Mueller, MD, PhD
Wendy W. Leisenring, ScD
Greg T. Armstrong, MD
Rita E. Weathers, MS
Marilyn Stovall, PhD
Charles A. Sklar, MD
Robert E. Goldsby, MD
Les L. Robison, PhD
Kevin R. Krull, PhD

Correspondence to
Dr. Mueller:
muellers@neuropeds.ucsf.edu

ABSTRACT

Objective: To estimate the rates and predictors of recurrent stroke among survivors of pediatric cancer who have had a first stroke.

Methods: The Childhood Cancer Survivor Study is a retrospective cohort study with longitudinal follow-up that enrolled 14,358 survivors (<21 years old at diagnosis; diagnosed 1970–1986; survived ≥ 5 years after cancer diagnosis) and followed them prospectively since 1994. We surveyed 443 survivors who reported a first stroke to identify recurrent stroke, and estimated recurrent stroke rates ≥ 5 years after cancer diagnosis.

Results: Among 329 respondents (74% response rate), 271 confirmed a first stroke at a median age of 19 years (range 0–53), and 70 reported a second stroke at a median age of 32 years (range 1–56). In a multivariable Cox proportional hazards model, independent predictors of recurrent stroke included cranial radiation therapy (CRT) dose of ≥ 50 Gy (vs none, hazard ratio [HR] 4.4; 95% confidence interval [CI] 1.4–13.7), hypertension (HR 1.9; 95% CI 1.0–3.5), and older age at first stroke (HR 6.4; 95% CI 1.8–23; for age ≥ 40 vs age 0–17 years). The 10-year cumulative incidence of late recurrent stroke was 21% (95% CI 16%–27%) overall, and 33% (95% CI 21%–44%) for those treated with ≥ 50 Gy of CRT.

Conclusion: Survivors of childhood cancer, particularly those previously treated with high-dose cranial radiation, have a high risk of recurrent stroke for decades after a first stroke. Although these strokes are mostly occurring in young adulthood, hypertension, an established atherosclerotic risk factor, independently predicts recurrent stroke in this population. **Neurology® 2015;85:1056–1064**

GLOSSARY

CCSS = Childhood Cancer Survivor Study; **CI** = confidence interval; **IQR** = interquartile range; **IRB** = institutional review board; **NDI** = National Death Index; **NF1** = neurofibromatosis type 1.

Prior studies have shown that childhood cancer survivors are at increased risk of stroke but many questions remain. Recent studies suggest that stroke risk remains elevated decades after cancer treatment.^{1–3} Cranial radiation therapy is a particularly strong predictor of first stroke, with an apparent dose-dependent effect.^{1,2,4,5} The etiology of stroke in these cases is likely a radiation-induced arteriopathy, which can lead to large or small vessel infarction, although the mechanisms underlying this arteriopathy have yet to be established.^{6,7} In a population-based cohort of children with ischemic stroke of any etiology, those with an underlying arteriopathy had an extraordinarily high risk of recurrent stroke: 66% within 5 years of the initial stroke.⁸ Children with radiation-induced arteriopathy most likely fall in this high-risk group, but there are few data regarding rates and predictors of recurrent stroke in pediatric cancer survivors. A better understanding of risk factors for recurrent stroke is needed to develop strategies for secondary stroke prevention in this high-risk population.

The Childhood Cancer Survivor Study (CCSS) is a retrospective cohort study with prospective follow-up.^{9,10} We used a previously identified subcohort with self-reported first stroke² and administered a new stroke survey to test the hypotheses that (1) stroke recurrence rates are high

Supplemental data
at Neurology.org

From the Departments of Neurology (H.J.F., S.M.), Pediatrics (H.J.F., S.M., R.E.G.), and Neurosurgery (S.M.), University of California, San Francisco; the Fred Hutchinson Cancer Research Center (K.S., W.W.L.), Clinical Statistics and Cancer Prevention Programs, Seattle, WA; St. Jude Children's Research Hospital (G.T.A., L.L.R., K.R.K.), Memphis, TN; the University of Texas M.D. Anderson Cancer Center (R.E.W., M.S.), Houston; and Memorial Sloan-Kettering Cancer Center (C.A.S.), New York, NY.

Go to Neurology.org for full disclosures. Funding information and disclosures deemed relevant by the authors, if any, are provided at the end of the article.

in childhood cancer survivors with first stroke and (2) cranial radiation therapy is a predictor of recurrent stroke.

METHODS Cohort. CCSS is an NIH-funded cohort study that originally identified 20,690 survivors of childhood cancer at 26 institutions in the United States and Canada, and recruited 14,358 of them into long-term follow-up (figure e-1 on the *Neurology*[®] Web site at Neurology.org). Eligibility criteria for enrollment are fully described elsewhere, and included age <21 years at cancer diagnosis, diagnosis between 1970 and 1986, survival for ≥ 5 years after diagnosis, and initial cancer treatment received at a CCSS collaborating institution.¹¹ Extensive details regarding baseline characteristics of patients (e.g., sex and race), the cancer type, radiation doses, and therapies received were collected at the time of enrollment. Late effects of cancer and cancer therapy have been assessed prospectively through 4 follow-up surveys available for review at <http://ccss.stjude.org>. Vital status for participants was assessed based on linkage to the National Death Index (NDI). A detailed description of the CCSS cohort, including comparisons of survey respondents vs nonrespondents, has been published previously.⁹⁻¹¹

Standard protocol approvals, registrations, and patient consents. The initial CCSS study was approved by institutional review boards (IRBs) at each collaborating institution and follow-up surveys, including the stroke survey, were approved by the IRB at St. Jude Children's Research Hospital, home of the Coordinating Center.

Stroke subcohort. CCSS patients were eligible for inclusion in the current study of recurrent stroke if they (or their proxy, if deceased) had responded either "yes" or "not sure" to questions about first stroke on any of the prior outcomes questionnaires. This cohort of patients with reported first stroke has been described recently.² All eligible patients were contacted by mail with a new survey focused on first and recurrent stroke. If a potential patient was deceased, a modified survey was sent to his or her proxy. Those who did not respond within 30 days to the mailing were subsequently contacted by telephone. In addition, the survey was mailed to nonrespondents 5 and 9 months after the first mailing, followed by telephone calls 30 days after each mailing.

2011 stroke survey. Patients/proxies were given the option of completing the survey by mail, online, or by telephone. The stroke survey (available at the CCSS Web site, <http://ccss.stjude.org>) first defined stroke using lay terminology, then asked the patient (or proxy) to confirm his or her prior report of a stroke. If confirmed, the survey asked detailed questions about the original stroke (presentation, evaluation, and treatment), and then asked if and when the patient had a recurrent stroke.

Data analysis. We used time-to-event methodology to estimate cumulative incidence rates and predictors of stroke recurrence. Because patients were enrolled in CCSS only if they had survived 5 years after cancer diagnosis, patients are considered to have entered the study at 5 years postdiagnosis when the time period of observation for late effects began, and this defines the cohort of subjects at risk of these conditions. The questionnaires asked about stroke retrospectively, thus the survivor/proxy could have reported a first or recurrent stroke at an age prior to 5 years after diagnosis. However, to avoid survival bias, such first and recurrent strokes are summarized in descriptive tables, but not included in the time-to-event analysis. The time-to-event analyses utilized left truncation, with

the period at risk for an observable recurrent stroke beginning at the time of the first stroke, or at 5 years postdiagnosis (the time point of study eligibility), whichever was later. Patients whose response to the recurrent stroke question was missing or "I don't know" were excluded from the analysis. Patients with missing age at recurrent stroke or age at recurrent stroke prior to study entry were also excluded (figure e-1).

Time from first stroke to initial recurrent stroke was based on reported integer ages, with age converted to a date equivalent to the midpoint of the year of the reported age. If the reported age at recurrent stroke was equivalent to the age at first stroke, 2 months (60 days) of follow-up was assigned, based on the median time found in other studies.⁸

In the absence of recurrent stroke, patients were censored at the date of the last questionnaire completed by the patient or his or her proxy, and death was treated as a competing risk event for the calculation of cumulative incidence.¹² Based on cause of death from the NDI, among all CCSS patients, there were 23 deaths considered to be stroke-related. However, 17 of these patients died after the last completed questionnaire, with no indication of a stroke on a prior outcome questionnaire, so they were not included in the 2011 stroke survey. Of the remaining 6 patients, 3 had proxy responses and were included in the time to event analysis, with 2 as recurrent stroke events and one censored at death (likely death from first stroke). We calculated unadjusted hazard ratios (HRs) as a measure of relative risk using Cox proportional hazards techniques, where time to event was censored at last contact or death. To determine independent predictors of recurrent stroke, we evaluated multivariable Cox proportional hazards models,¹³ using univariate screening with a *p* value cutoff of 0.10 for inclusion in the model. Sex, race/ethnicity (white non-Hispanic vs other), and age at diagnosis were included in all models as a priori covariates. The primary predictor of interest was total dose of cranial radiation therapy, as defined and categorized for the CCSS study of predictors of first stroke.² Other predictors included age at first stroke, cancer type, chemotherapy, diagnosis of neurofibromatosis type 1 (NF1), hypertension, smoking, and diabetes. NF1 was based on self-report on any questionnaire. Hypertension, smoking, and diabetes were treated as time-dependent variables that switched from not present to present at the earliest self-reported age at diagnosis or usage, and were defined as in our prior report.²

RESULTS Within the overall CCSS cohort of 14,358 childhood cancer survivors followed for a mean of 23 years postdiagnosis, a total of 292 had reported a first stroke after study entry by the time of the third follow-up CCSS survey. An additional 172 patients reported a stroke prior to study entry (i.e., within the first 5 years after cancer diagnosis), and 25 indicated "not sure" on the third survey. Of these 489 patients with possible first stroke, questionnaires were mailed to 334 live patients and 109 proxies of deceased patients; 329 responses were received (74% response rate; figure e-1). Key characteristics of subjects such as sex, race, age at cancer diagnosis, age at first stroke, age at last follow-up, and radiation dose did not differ significantly between those who responded to the survey compared to those who did not (χ^2 test; see table e-1).

First stroke in childhood cancer survivors. Among the respondents, 271 confirmed a first stroke. The median time from cancer diagnosis to first stroke was 10 years (interquartile range [IQR] 21 years). The most common underlying cancer types were brain tumors (44%) and leukemia (28%); the majority had received cranial radiation, although 22% of the stroke cohort had received neither cranial nor neck radiation (table e-2). The median age at first stroke was 19 years (table e-2). The most common presenting features were unilateral weakness (64%) and difficulty walking (63%) and speaking (60%); a minority of respondents (37%) reported complete recovery from the first stroke. Among 79 patients with a self-reported ischemic stroke, 51 (65%) reported poststroke treatment with an antithrombotic agent (antiplatelet or anticoagulant, in hospital or at home), as well as 13 (20%) of 65 patients with a self-reported hemorrhagic stroke.

Recurrent stroke in childhood cancer survivors. Of the 271 patients with first stroke, 70 reported a second stroke, 164 reported no recurrence, and 37 were unsure whether there was a recurrence or skipped the question. The median age at second stroke was 32 years (table 1); the median time from cancer diagnosis to second stroke was 23 years (IQR 19 years). The most common presenting features were difficulty speaking (64%) and walking (61%) and unilateral weakness (47%); only 27% reported a complete recovery from the second stroke. Among the 271 patients with first stroke, 58 could not be included in the time-to-event analysis (figure e-1); of the remaining 213, 52 reported a second stroke. The 10-year cumulative incidence of second stroke was 21% (95% confidence interval [CI] 16–27) overall (figure 1A), 33% (95% CI 21–44) for those treated with ≥ 50 Gy of cranial radiation, and 11% (95% CI 0%–21%) for those who received no radiation (table 2).


Predictors of recurrent stroke in childhood cancer survivors. Stratified cumulative incidence curves suggested that cranial radiation dose, cancer type, and age at first stroke modified recurrent stroke risk (figure 1, B–D); total cranial radiation dose of ≥ 50 Gy, brain tumors, and age > 17 years at first stroke were significant predictors of recurrence on univariate analysis (table 3). Hypertension (reported at any point prior to the second stroke or loss to follow-up) was also predictive in a univariate analysis. These remained independent predictors of recurrence on multivariate analysis (table 4); cancer type was not included in the final model due to collinearity with cranial radiation dose, and history of NF1 could not be included since only 3 patients reported a positive history.

DISCUSSION Survivors of childhood cancer with self-reported first stroke are at high risk for

Table 1 Characteristics of second stroke in 70 childhood cancer survivors reporting a recurrent stroke in the 2011 stroke survey

Characteristics	Median (range) or n (%)
Age at second stroke, y	32 (1-56)
Age at second stroke, y (categorical)	
<18	15 (21)
18–29	14 (20)
30–39	19 (27)
40+	15 (21)
Missing	7 (10)
Type of second stroke	
Ischemic	21 (30)
Hemorrhagic	15 (21)
Not sure	25 (36)
Missing	9 (13)
Second stroke symptoms lasted >24 h	
Yes	49 (70)
No	15 (21)
Do not know	6 (9)
Characteristics of second stroke	
Difficulty speaking	45 (64)
Difficulty walking	43 (61)
Unilateral weakness	33 (47)
Visual changes	30 (43)
Headache at the time of stroke	25 (36)
Seizure at the time of stroke	23 (33)
Unilateral numbness	23 (33)
Dizziness	19 (27)
Bilateral weakness	14 (20)
Bilateral numbness	8 (11)
No symptoms (silent stroke)	5 (7)
Brain imaging performed	
Both CT and MRI	21 (30)
CT	15 (21)
MRI	13 (19)
No brain imaging done	11 (16)
Imaging not known	10 (14)
Recovery from second stroke	
Complete	19 (27)
Partial	28 (40)
No recovery	17 (24)
Do not know	6 (9)
More than one recurrent stroke?	
Yes	22 (31)
No	48 (69)

Figure 1 Cumulative incidence of recurrent stroke in childhood cancer survivors



Cumulative incidence of recurrent stroke after study entry among 213 childhood cancer survivors with self-reported first stroke and responses regarding recurrent stroke on the 2011 stroke questionnaire: unstratified with 95% confidence interval (A), and stratified by maximum dose of cranial radiation therapy to any brain segment (B), cancer type (C), and age in years at first stroke (D). Curves begin at the time of first stroke or, if first stroke occurred prior to study entry, at study entry. Curves are displayed out to time point where fewer than 10 survivors were at risk. CNS = central nervous system tumors; HD = Hodgkin disease.

recurrent stroke in the decade following the first stroke. Predictors of recurrent stroke are similar to predictors of first stroke, including high-dose cranial radiation therapy and hypertension. Older age at first stroke also predicted risk of recurrence.

The cumulative rate of recurrent stroke in the general population of young adults (<50 years of age) has been estimated at approximately 10% by 10 years after a first ischemic stroke.^{14,15} In our cohort of childhood cancer survivors, the first strokes tended to occur in young adulthood, but the recurrent stroke rate was, overall, double that for young adults in general, with a 10-year cumulative rate of 21%. Prior cranial radiation therapy (≥ 50 Gy) was a significant predictor of recurrent stroke risk. Those who received no cranial radiation had a recurrent stroke risk of 11% at 10 years, similar to young adults in general; the risk

tripled for those who received ≥ 50 Gy (33% at 10 years). Prior neck radiation was not a significant predictor of recurrent stroke risk in our study. However, our study was likely underpowered to detect an association between neck radiation and recurrent stroke.

There is one published estimate of recurrent stroke risk in this setting: a single-institution retrospective study, performed by authors of this report (H.J.F., S.M.), examined stroke risk among 19 childhood cancer survivors who had been treated with high-dose cranial or cervical radiation and reported a first stroke at any time (including those in the first 5 years after cancer diagnosis).³ Of the 19 patients with a first stroke (median age at first stroke of 24 years), 6 had recurrent strokes at a median interval of 15 months (IQR 6 months–3.2 years), yielding a cumulative 10-year recurrence estimate of 59% (95% CI 27–92).

Table 2 Incidence of recurrent stroke after study entry^a among 213 childhood cancer survivors with self-reported first stroke, and responses regarding recurrent stroke on the 2011 survey, stratified by cancer type and radiation therapy

Group	First stroke, n	Recurrent stroke, n	10-y cumulative incidence		HR (95% CI)	p Value
			Rate, %	95% CI		
All cancer survivors	213	52	21	16-27		
With RT	157	45	24	17-31	3.2 (1.1-8.9)	0.03
Without RT	37	4	11	1-21	Ref	
Unknown RT	19	3				
Brain tumor	83	29				
With RT	70	26	31	20-43	4.3 (0.6-32.0)	0.15
Without RT	8	1	NE		Ref	
Unknown RT	5	2				
Leukemia	68	8				
With RT	49	8	17	6-28	NE	
Without RT	11	0	NE			
Unknown RT	8	0				
Hodgkin disease	21	5				
With RT	18	4	20	0-39	0.6 (0.1-6.3)	0.69
Without RT	2	1	NE		Ref	
Unknown RT	1	0				

Abbreviations: CI = confidence interval; HR = hazard ratio for recurrent stroke in those with vs without exposure to radiation therapy; NE = nonestimable due to low number of outcomes; Ref = reference; RT = prior direct cranial radiation therapy or scatter.

^aSubjects entered the study observation period at 5 years post cancer diagnosis.

This higher point estimate, when compared with 33% (95% CI 21-44) for the CCSS stroke cohort treated with ≥ 50 Gy cranial radiation, may suggest underreporting of stroke in the current study. However, other methodologic differences, including differences in sample size, may also explain the apparent difference.

The mechanism underlying how cranial radiation increases stroke risk remains to be elucidated. Studies have shown that radiation therapy is associated with an occlusive disease of arteries located within or nearby the radiation field.^{7,16} Among children with arterial ischemic stroke of any cause, the presence of a cerebral arteriopathy, and of moyamoya in particular, has been shown to be the strongest predictor of recurrent stroke.^{8,17} While the development of moyamoya is a relatively early phenomenon, the elevated risk of first stroke in childhood cancer survivors appears to persist, and even increase, decades after treatment, suggesting a second mechanism for a delayed radiation arteriopathy.^{1,2}

A prior CCSS study found that hypertension and black race—both established risk factors for atherosclerosis^{18,19}—independently increased risk of first stroke in childhood cancer survivors.² These findings,

in addition to extensive clinical and laboratory evidence suggesting that neck radiation causes accelerated atherosclerosis of cervical vessels,^{7,20,21} led to a hypothesis that cranial radiation may increase stroke risk by accelerating the development of intracranial atherosclerosis. In our study, we similarly found that hypertension independently predicted risk of recurrent stroke; there was a nonsignificant trend toward an association with diabetes. Age ≥ 17 years at the time of first stroke also predicted recurrence, with risk increasing with each decade of advancing age. A recent analysis from the CCSS also showed that childhood cancer survivors have premature aging and early onset of cardiovascular disease.²² This lends further support to the hypothesis that early-onset atherosclerosis is on the causal pathway from cranial radiation to ischemic stroke, and suggests that earlier screening for modifiable atherosclerotic risk factors could be an avenue for improving both cardiovascular and cerebrovascular outcomes.

Strengths of this study include the relatively large size of the cohort, the long duration of follow-up, and the quality of the data on predictors such as cancer treatments. However, our findings must be considered in the context of certain limitations. It was not

Table 3 Univariate predictors of recurrent stroke after study entry among 213 childhood cancer survivors with self-reported first stroke and responses regarding recurrent stroke

Characteristics	Recurrence (n = 52), n (%)	No recurrence (n = 161), n (%)	HR (95% CI)	p Value
Male sex	29 (56)	82 (51)	1.3 (0.8-2.3)	0.32
Race				
White, non-Hispanic	39 (75)	129 (80)	Ref	
Black	4 (8)	8 (5)	1.6 (0.6-4.4)	0.39
Other	9 (17)	24 (15)	1.3 (0.6-2.7)	0.49
Age at cancer diagnosis, y, median (range)	8 (0-20)	7 (0-20)		
Age at cancer diagnosis, y				
0-4	14 (27)	58 (36)	0.7 (0.3-1.6)	0.43
5-9	18 (35)	35 (22)	1.4 (0.6-3.0)	0.39
10-14	10 (19)	38 (24)	0.9 (0.4-2.1)	0.75
15-20	10 (19)	30 (19)	Ref	
Cancer diagnosis				
Brain tumor	29 (56)	54 (34)	3.5 (1.6-7.7)	0.0017
Leukemia	8 (15)	60 (37)	Ref	
Hodgkin disease	5 (10)	16 (10)	2.7 (0.9-8.2)	0.090
Other ^a	10 (19)	31 (19)	2.3 (0.9-5.8)	0.082
Cranial radiation therapy, maximum dose, Gy				
None	4 (8)	33 (20)	Ref	
0.01-29.9	6 (12)	38 (24)	1.3 (0.4-4.5)	0.70
30-49.9	4 (8)	10 (6)	3.3 (0.8-13.4)	0.088
≥50	26 (50)	41 (25)	4.8 (1.7-13.7)	0.0038
Indirect	9 (17)	23 (14)	3.4 (1.0-11.2)	0.043
Unknown	3 (6)	16 (10)	—	
Any neck radiation				
Yes	12 (23)	42 (26)	1.0 (0.5-1.9)	0.92
No	37 (71)	103 (64)	Ref	
Unknown	3 (6)	16 (10)	—	
Radiation to neck or brain				
Direct neck, no direct brain radiation	5 (10)	14 (9)	2.0 (0.6-6.0)	0.24
Direct brain radiation	36 (69)	90 (56)	2.0 (0.9-4.2)	0.080
No neck or brain direct radiation	8 (15)	41 (25)	Ref	
Unknown	3 (6)	16 (10)	—	
Age at first stroke, y, median (range)	30 (2-49)	17 (0-49)		
Age at first stroke, y				
0-17	12 (23)	85 (53)	Ref	
18-29	13 (25)	27 (17)	4.5 (2.0-10.4)	0.0003
30-39	19 (37)	32 (20)	6.4 (2.9-14.4)	<0.0001
≥40	8 (15)	17 (11)	5.9 (2.2-15.6)	0.0004
Time from cancer diagnosis to first stroke, y				
Stroke before cancer diagnosis	0 (0)	5 (3)		
<2	5 (10)	46 (29)	Ref	
2-5	4 (8)	23 (14)	1.7 (0.5-6.3)	0.44
6-10	4 (8)	15 (9)	4.1 (1.1-15.5)	0.040
≥11	39 (75)	72 (45)	9.2 (3.4-25.0)	<0.0001

Continued

Table 3 Continued

Characteristics	Recurrence (n = 52), n (%)	No recurrence (n = 161), n (%)	HR (95% CI)	p Value
First stroke symptom duration >24 h	40 (77)	96 (60)	1.9 (1.0-3.6)	0.057
Presentation with hemiparesis	30 (58)	111 (69)	0.6 (0.3-1.0)	0.064
Stroke risk factors ^b				
Narrowing of blood vessels to brain	4 (8)	9 (6)	1.3 (0.5-3.6)	0.62
Moyamoya	5 (10)	5 (3)	2.6 (1.0-6.5)	0.044
Hypertension	24 (46)	48 (30)	3.3 (1.9-5.7)	<0.0001
Diabetes mellitus	5 (10)	12 (7)	2.3 (0.9-5.7)	0.08
Smoking (ever)	7 (13)	43 (27)	0.7 (0.3-1.6)	0.45

Abbreviations: CI = confidence interval; HR = hazard ratio from univariate Cox proportional hazards models; Ref = reference.

Frequencies shown here represent onset at any time prior to recurrence/last follow-up.

^aWilms tumor, non-Hodgkin lymphoma, soft tissue sarcoma, bone cancer, neuroblastoma.

^bHypertension, diabetes, and smoking were treated as time-dependent in the models (i.e., the value of the covariate for an individual could change with age).

feasible to obtain medical records or brain imaging to confirm the reported strokes in our cohort. Hence, all strokes (first and recurrent) were measured by self-report or proxy report, which likely led to some misclassification, and also precluded reliable subclassification of stroke type (ischemic vs hemorrhagic).

Subclinical or silent strokes may have gone undetected, resulting in an underestimation of total stroke frequency in the cohort. However, the 2011 stroke survey improved upon prior CCSS survey measurements of stroke outcomes by providing lay definitions of stroke before asking respondents to confirm their report of stroke, and by including questions regarding stroke presentation and treatment. Indeed, 55 previously reported first strokes were not confirmed on the stroke survey, suggesting that the lay definitions may have improved the respondents' understanding of the question. Furthermore, our high response rate to the stroke survey suggests that there was no significant participation bias (i.e., both patients with and without recurrent stroke responded to the stroke survey). Our measurements of atherosclerotic risk factors were also based on self-report, and we had to make assumptions regarding the onset of these risk factors. Also, because patients were enrolled in CCSS only if they survived 5 years post cancer diagnosis, our study is missing children who died within the first 5 years (a group that may have been at particularly high risk for first and recurrent stroke). Hence, our results are only generalizable to ≥ 5 -year survivors of childhood cancer, and not to children with more recent diagnoses. Cerebral or cervical arteriopathies are the strongest predictor of recurrent stroke in children⁸; however, we had no access to imaging, including vascular imaging, so could not assess whether a cerebral arteriopathy was on the causal pathway between radiation and recurrent stroke. Finally, although we collected data on antithrombotic use, because we could not reliably distinguish ischemic from hemorrhagic stroke, and because of concerns for confounding by indication, we could not perform a meaningful analysis of efficacy of such therapy in reducing risk of recurrent ischemic stroke.

Table 4 Independent predictors of recurrent stroke after study entry among 213 childhood cancer survivors with self-reported first stroke and responses regarding recurrent stroke

Predictor	HR (95% CI)	p Value
Male sex	0.9 (0.5-1.7)	0.81
Black or other race vs white non-Hispanic	1.7 (0.8-3.5)	0.17
Age at cancer diagnosis, y		
0-4	1.2 (0.4-3.1)	0.78
5-9	1.7 (0.7-4.0)	0.26
10-14	0.6 (0.2-1.7)	0.35
15-20	Ref	
Cranial radiation therapy, maximum dose		
None	Ref	
0.01-29.9 Gy	1.7 (0.5-6.3)	0.41
30-49.9 Gy	3.1 (0.7-13.4)	0.12
≥ 50 Gy	4.4 (1.4-13.7)	0.011
Indirect radiation	2.0 (0.6-6.6)	0.27
Age at first stroke, y		
0-17	Ref	
18-29	3.4 (1.3-8.8)	0.014
30-39	5.4 (2.0-15.0)	0.0012
≥ 40	6.4 (1.8-22.6)	0.0039
Hypertension	1.9 (1.0-3.5)	0.052

Abbreviations: CI = confidence interval; HR = hazard ratio from multivariate Cox proportional hazards models (all variables included in the model are shown); Ref = reference.

Dramatic improvements in survival rates of childhood cancers make more apparent the later effects of life-saving cancer therapies. Stroke is a particularly devastating consequence that can not only lead to physical disability, but can worsen the cognitive impairment that many survivors develop as a direct effect of cranial radiation therapy, or the cancer itself. A better understanding of risk factors for stroke, and the underlying mechanisms, creates opportunities for primary and secondary stroke prevention. A role for accelerated atherosclerosis suggests particularly low-hanging fruit for risk modification in this population: the early identification and treatment of modifiable atherosclerotic risk factors like hypertension. Screening guidelines might need to be adjusted to assess for these risk factors in a more uniform way in this at-risk population.

AUTHOR CONTRIBUTIONS

H.J. Fullerton: involved in design and conceptualization of the study, analysis and interpretation of the data, and drafting the manuscript. K. Stratton: involved in design and conceptualization of the study, analysis and interpretation of the data, and drafting the manuscript. S. Mueller: involved in design and conceptualization of the study, analysis and interpretation of the data, and drafting the manuscript. W. Leisenring: involved in design and conceptualization of the study, analysis and interpretation of the data, and drafting the manuscript. G.T. Armstrong: involved in design and conceptualization of the study and drafting the manuscript. R.E. Weathers: involved in design and conceptualization of the study and drafting the manuscript. M. Stovall: involved in design and conceptualization of the study, analysis and interpretation of the data, and drafting the manuscript. C.A. Sklar: involved in design and conceptualization of the study and drafting the manuscript. R.E. Goldsby: involved in design and conceptualization of the study and drafting the manuscript. L.L. Robison: involved in design and conceptualization of the study, analysis and interpretation of the data, and drafting the manuscript. K.R. Krull: involved in design and conceptualization of the study, analysis and interpretation of the data, and drafting the manuscript.

ACKNOWLEDGMENT

The authors thank the participants and their families for their participation in the CCSS and additional stroke survey.

STUDY FUNDING

Supported by the National Cancer Institute (U24 CA 55727 to L.L.R.), Cancer Center Support (CORE) (grant CA21765), and the American Lebanese-Syrian Associated Charities (ALSAC). Dr. Mueller and Dr. Fullerton were supported by a private donation from the LaRoche family, and Dr. Mueller by the National Center for Advancing Translational Sciences, NIH, through UCSF-CTSI grant number KL2TR000143, and the Frank A. Campini Foundation.

DISCLOSURE

The authors report no disclosures relevant to the manuscript. Go to Neurology.org for full disclosures.

Received December 6, 2014. Accepted in final form May 21, 2015.

REFERENCES

1. Bowers DC, Liu Y, Leisenring W, et al. Late-occurring stroke among long-term survivors of childhood leukemia and brain tumors: a report from the Childhood Cancer Survivor Study. *J Clin Oncol* 2006;24:5277–5282.

2. Mueller S, Fullerton HJ, Stratton K, et al. Radiation, atherosclerotic risk factors and stroke risk in survivors of pediatric cancer: a report from the Childhood Cancer Survivor Study. *Int J Radiat Oncol Biol Phys* 2013;86:649–655.
3. Mueller S, Sear K, Hills NK, et al. Risk of first and recurrent stroke in childhood cancer survivors treated with cranial and cervical radiation. *Int J Radiat Oncol Biol Phys* 2013;86:643–648.
4. Haddy N, Mousannif A, Tukenova M, et al. Relationship between the brain radiation dose for the treatment of childhood cancer and the risk of long-term cerebrovascular mortality. *Brain* 2011;134:1362–1372.
5. Campen CJ, Kranick SM, Kasner SE, et al. Cranial irradiation increases risk of stroke in pediatric brain tumor survivors. *Stroke* 2012;43:3035–3040.
6. Fouladi M, Langston J, Mulhern R, et al. Silent lacunar lesions detected by magnetic resonance imaging of children with brain tumors: a late sequela of therapy. *J Clin Oncol* 2000;18:824–831.
7. Plummer C, Henderson RD, O'Sullivan JD, Read SJ. Ischemic stroke and transient ischemic attack after head and neck radiotherapy: a review. *Stroke* 2011;42:2410–2418.
8. Fullerton HJ, Wu YW, Sidney S, Johnston SC. Risk of recurrent childhood arterial ischemic stroke in a population-based cohort: the importance of cerebrovascular imaging. *Pediatrics* 2007;119:495–501.
9. Robison LL, Armstrong GT, Boice JD, et al. The Childhood Cancer Survivor Study: a National Cancer Institute-supported resource for outcome and intervention research. *J Clin Oncol* 2009;27:2308–2318.
10. Leisenring WM, Mertens AC, Armstrong GT, et al. Pediatric cancer survivorship research: experience of the Childhood Cancer Survivor Study. *J Clin Oncol* 2009;27:2319–2327.
11. Robison LL, Mertens AC, Boice JD, et al. Study design and cohort characteristics of the Childhood Cancer Survivor Study: a multi-institutional collaborative project. *Med Pediatr Oncol* 2002;38:229–239.
12. Gooley TA, Leisenring W, Crowley J, Storer BE. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. *Stat Med* 1999;18:695–706.
13. Kalbfleisch JD, Prentice RL. *The Statistical Analysis of Failure Time Data*. New York: John Wiley & Sons; 1980.
14. Putaala J, Haapaniemi E, Kurkinen M, Salonen O, Kaste M, Tatlisumak T. Silent brain infarcts, leukoaraiosis, and long-term prognosis in young ischemic stroke patients. *Neurology* 2011;76:1742–1749.
15. Kappelle LJ, Adams HP Jr, Heffner ML, Torner JC, Gomez F, Biller J. Prognosis of young adults with ischemic stroke: a long-term follow-up study assessing recurrent vascular events and functional outcome in the Iowa Registry of Stroke in Young Adults. *Stroke* 1994;25:1360–1365.
16. Omura M, Aida N, Sekido K, Kakehi M, Matsubara S. Large intracranial vessel occlusive vasculopathy after radiation therapy in children: clinical features and usefulness of magnetic resonance imaging. *Int J Radiat Oncol Biol Phys* 1997;38:241–249.
17. Ganesan V, Prengler M, Wade A, Kirkham FJ. Clinical and radiological recurrence after childhood arterial ischemic stroke. *Circulation* 2006;114:2170–2177.
18. Waddy SP, Cotsonis G, Lynn MJ, et al. Racial differences in vascular risk factors and outcomes of patients with

- intracranial atherosclerotic arterial stenosis. *Stroke* 2009; 40:719–725.
19. Mozaffarian D, Benjamin EJ, Go AS, et al. Heart disease and stroke statistics—2015 update: a report from the American Heart Association. *Circulation* 2015;131:e29–322.
 20. Muzaffar K, Collins SL, Labropoulos N, Baker WH. A prospective study of the effects of irradiation on the carotid artery. *Laryngoscope* 2000;110:1811–1814.
 21. De Bruin ML, Dorresteijn LD, van't Veer MB, et al. Increased risk of stroke and transient ischemic attack in 5-year survivors of Hodgkin lymphoma. *J Natl Cancer Inst* 2009;101:928–937.
 22. Armstrong GT, Kawashima T, Leisenring W, et al. Aging and risk of severe, disabling, life-threatening, and fatal events in the childhood cancer survivor study. *J Clin Oncol* 2014;32:1218–1227.

This Week's *Neurology*[®] Podcast



Acute headache diagnosis in pregnant women: A hospital-based study (see p. 1024)

This podcast begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the September 22, 2015, issue of *Neurology*. In the second segment, Dr. Teshamae Monteith talks with Dr. Matthew Robbins about his paper on acute headache diagnosis in pregnant women. Dr. Sarah Wesley reads the e-Pearl of the week about primary lateral sclerosis. In the next part of the podcast, Dr. Andy Southerland focuses his interview with Dr. Jack Tsao on the topic of reimbursement, credentialing, and policy updates.

Disclosures can be found at Neurology.org.

At Neurology.org, click on “RSS” in the Neurology Podcast box to listen to the most recent podcast and subscribe to the RSS feed.

CME Opportunity: Listen to this week's *Neurology* Podcast and earn 0.5 AMA PRA Category 1 CME Credits™ by answering the multiple-choice questions in the online Podcast quiz.

Quality CME. Expert Faculty. Improved Patient Care.

Register Today for the AAN Fall Conference!

Register today for the 2015 AAN Fall Conference, set for October 16 through 18 at The Cosmopolitan of Las Vegas. Learn from expert faculty as they present the latest clinical and practice management advances to help you stay current, provide the best patient care, and keep your practice thriving—all while earning up to 18.75 CME in three days! New for 2015—four courses now qualify for self-assessment (SA) CME (get up to 15 SA credits total).

Early registration and hotel discounts end September 10. Visit AAN.com/view/Fall to learn more and register today.